ORCHESTRA BIOMED HOLDINGS INC. - ORDINARY SHARES

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

19 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 16:34:21 By Nasdaq GlobeNewswire

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

08 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

26 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

07 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed to Present at the Jefferies Global Healthcare Conference

01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

12 May 2023 09:15:18 By Nasdaq GlobeNewswire

Orchestra BioMed to Present at Upcoming Investor Conferences

07 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

24 Feb 2023 08:00:00 By Nasdaq GlobeNewswire